TRVI – trevi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.
Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Form 10-K Trevi Therapeutics, Inc. For: Dec 31
Form 8-K Trevi Therapeutics, Inc. For: Mar 17
Form 8-K Trevi Therapeutics, Inc. For: Mar 09
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Galletta Christopher
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.